Kidney disease associated with plasma cell dyscrasias.

Plasma cell dyscrasias are frequently encountered malignancies often associated with kidney disease through the production of monoclonal immunoglobulin (Ig). Paraproteins can cause a remarkably diverse set of pathologic patterns in the kidney and recent progress has been made in explaining the molecular mechanisms of paraprotein-mediated kidney injury. Other recent advances in the field include the introduction of an assay for free light chains and the use of novel antiplasma cell agents that can reverse renal failure in some cases. The role of stem cell transplantation, plasma exchange, and kidney transplantation in the management of patients with paraprotein-related kidney disease continues to evolve.

[1]  Philippe Moreau,et al.  Autologous hematopoietic stem-cell transplantation for multiple myeloma. , 2009, The New England journal of medicine.

[2]  G. Bhagat,et al.  Light chain proximal tubulopathy. , 2009, Kidney international.

[3]  X. Gu,et al.  Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. , 2009, Archives of pathology & laboratory medicine.

[4]  B. Barlogie,et al.  Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. , 2009, Archives of pathology & laboratory medicine.

[5]  V. D’Agati,et al.  Proliferative glomerulonephritis with monoclonal IgG deposits. , 2009, Journal of the American Society of Nephrology : JASN.

[6]  T. Spitzer,et al.  Light Chains: Heavy Burden in Kidney Transplantation , 2009, Transplantation.

[7]  K. Anderson,et al.  The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. , 2009, Blood.

[8]  I. Borrello.  Lenalidomide in renal insufficiency – balancing the risks and benefits , 2009, British journal of haematology.

[9]  A. Komatsuda,et al.  Monoclonal immunoglobulin deposition disease associated with membranous features. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  M. Rudnicki,et al.  Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells , 2008, Journal of Pharmacology and Experimental Therapeutics.

[11]  G. Mead,et al.  Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[12]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  P. Vermeersch,et al.  More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B‐cell disorders in routine clinical practice , 2008, British journal of haematology.

[14]  N. Heyne,et al.  European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial , 2008, Trials.

[15]  Benjamin Deroure,et al.  Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[16]  A. Dispenzieri,et al.  Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. , 2008, Kidney international.

[17]  R. Neuwirth,et al.  Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study , 2008, Leukemia.

[18]  B. Barlogie,et al.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 , 2008, British journal of haematology.

[19]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[20]  J. Leonard,et al.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. , 2008, Blood.

[21]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[22]  R. Steingart,et al.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. , 2008, The New England journal of medicine.

[23]  M. Dimopoulos,et al.  Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens , 2007, Leukemia & lymphoma.

[24]  K. Anderson,et al.  The evolving background for high-dose treatment for myeloma , 2007, Bone Marrow Transplantation.

[25]  N. Munshi,et al.  The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. , 2007, Hematology/oncology clinics of North America.

[26]  R. Greil,et al.  Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study. , 2007 .

[27]  S. Daval,et al.  Risk of antigen excess in serum free light chain measurements. , 2007, Clinical chemistry.

[28]  V. Leblond,et al.  The Case |[mid]| The case presentation , 2007 .

[29]  J. Drach,et al.  Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma , 2007, Haematologica.

[30]  V. Leblond,et al.  Make your diagnosis. Multiple myeloma-associated with spurious hyperphosphatemia. , 2007, Kidney international.

[31]  J. Leonard,et al.  Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy , 2007, British journal of haematology.

[32]  B. Barlogie,et al.  High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. , 2007, Blood.

[33]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[34]  N. Munshi,et al.  New drugs for myeloma. , 2007, The oncologist.

[35]  P. Dickman,et al.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[37]  P. Sanders,et al.  Immunoglobulin light chains generate hydrogen peroxide. , 2007, Journal of the American Society of Nephrology : JASN.

[38]  M. Dimopoulos,et al.  Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. , 2007, Haematologica.

[39]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[40]  Joseph D Tariman,et al.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. , 2007, Blood.

[41]  C. Stowell,et al.  Light‐chain removal by plasmapheresis in myeloma‐associated renal failure , 2007, Transfusion.

[42]  H. Jäck,et al.  Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. , 2007, Cancer research.

[43]  V. D’Agati,et al.  Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. , 2006, Kidney international.

[44]  G. Merlini,et al.  Dangerous small B-cell clones. , 2006, Blood.

[45]  R. Colvin,et al.  Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[46]  M. Cogné,et al.  Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. , 2006, Blood.

[47]  A. Nozza,et al.  Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. , 2006, Clinical therapeutics.

[48]  Allan S. Brett,et al.  Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .

[49]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[50]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Amit X Garg,et al.  Plasma Exchange When Myeloma Presents as Acute Renal Failure , 2005, Annals of Internal Medicine.

[52]  C. Geisler,et al.  Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure , 2005, European journal of haematology.

[53]  T. Larson,et al.  Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[54]  A. Levine,et al.  Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients , 2005 .

[55]  D. Esseltine,et al.  Bortezomib in recurrent and/or refractory multiple myeloma , 2005, Cancer.

[56]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[57]  J. Cardelli,et al.  Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns , 2004, Laboratory Investigation.

[58]  P. Höglund,et al.  Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis , 2003, The Journal of pharmacy and pharmacology.

[59]  F. Locatelli,et al.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  P. Fine,et al.  Toxic acute tubular necrosis following treatment with zoledronate (Zometa). , 2003, Kidney international.

[61]  N. Russell,et al.  Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia , 2003, British journal of haematology.

[62]  M. Pepys,et al.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.

[63]  S. Sengul,et al.  Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. , 2003, American journal of physiology. Renal physiology.

[64]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[65]  S. Sengul,et al.  Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. , 2002, Kidney international.

[66]  J. Katzmann,et al.  Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains , 2002 .

[67]  M. Alyanakian,et al.  Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. , 2001, Journal of the American Society of Nephrology : JASN.

[68]  I. Roberts,et al.  Recurrence of Light Chain Nephropathy in a Renal Allograft , 2001, American Journal of Nephrology.

[69]  H Birn,et al.  Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. , 2001, American journal of physiology. Renal physiology.

[70]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[71]  M. Drayson,et al.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. , 2001, Clinical chemistry.

[72]  A M Zickerman,et al.  IgA myeloma presenting as Henoch-Schönlein purpura with nephritis. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[73]  L. Knudsen,et al.  Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.

[74]  J. Ghiso,et al.  Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition. , 1999, The American journal of pathology.

[75]  M. Gertz,et al.  Acquired Fanconi's syndrome associated with monoclonal gammopathies. , 1999, Hematology/oncology clinics of North America.

[76]  P. Boyle,et al.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study , 1999, The Lancet.

[77]  H. Rabb,et al.  Acute renal failure from multiple myeloma precipitated by ACE inhibitors. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  E. Montserrat,et al.  Patients with multiple myeloma requiring long‐term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases , 1995, British journal of haematology.

[79]  C. Chang,et al.  A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. , 1995, Biochemistry.

[80]  E. Holmberg,et al.  Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients , 1994, European journal of haematology.

[81]  M. Hurle,et al.  A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[82]  G. Herrera,et al.  Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[83]  T. Tsukahara,et al.  Distribution of cathepsins B and H in rat tissues and peripheral blood cells. , 1985, Journal of biochemistry.

[84]  A. Solomon,et al.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). , 1982, The Journal of clinical investigation.

[85]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[86]  H. Johnsen,et al.  the Nordic Myeloma Study Group , 2009 .

[87]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[88]  O. Grenet,et al.  Monitoring kidney safety in drug development: emerging technologies and their implications. , 2008, Current opinion in drug discovery & development.

[89]  E. Kastritis,et al.  SPOTLIGHT REVIEW Treatment of plasma cell dyscrasias with lenalidomide , 2008 .

[90]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[91]  E. Bergstralh,et al.  Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[92]  M. Gertz,et al.  Long-term outcome of renal transplantation in light-chain deposition disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[93]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[94]  Hiroshi Sato,et al.  Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[95]  J. Katzmann,et al.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. , 2002, Clinical chemistry.

[96]  L. Rostaing,et al.  Long-term follow-up of monoclonal gammopathy of undetermined significance in transplant patients. , 1994, American journal of nephrology.

[97]  B. Barlogie,et al.  The growth fraction of human myeloma cells. , 1981, Blood.